Scientific Reference

Semax

Evidence profile: Predominantly preclinical

Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment, developed in Russia and studied for its effects on the central nervous system. The published literature describes rapid increases in BDNF expression and modulation of dopaminergic and serotonergic signalling. Administered intranasally in study protocols, it is described as reaching the CNS via the olfactory epithelium and trigeminal pathways rather than crossing the blood-brain barrier. Semax is not an approved medicine in the United Kingdom. Supplied strictly as a research compound for laboratory use.